文献速递精神分裂症与精神病性障碍

精神分裂症认知试验中的安慰剂效应与练习效应

Placebo Response and Practice Effects in Schizophrenia Cognition Trials.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

该研究系统评估了精神分裂症相关认知障碍患者在接受安慰剂时MCCB测量的练习效应和安慰剂效应,发现平均变化仅为1.8个T分(0.18 SD),与练习效应基本一致,且安慰剂效应微小,不能解释有效治疗与安慰剂无法区分的原因。

要点

  • 精神分裂症认知试验中安慰剂组MCCB平均改善仅0.18 SD,练习效应与此相当。
  • 基线抑郁焦虑重、动机强及筛查到基线改善小的患者安慰剂效应更明显。
  • 基线认知低于常模2.28 SD,安慰剂改善<0.2 SD提示无天花板效应。

核心结论

  • 安慰剂效应微小,与练习效应基本一致,不能解释有效治疗与安慰剂无法区分。

研究设计与样本

  • 对12项随机安慰剂对照试验中813例精神分裂症患者的盲法数据回顾,其中779例有基线和至少一次随访数据。

主要发现

  • 安慰剂组MCCB总分平均变化1.8个T分(95% CI 1.40-2.18),相当于0.18 SD。
  • 7项有基线前评估的研究中练习效应与基线后安慰剂变化基本一致。
  • 基线抑郁/焦虑更重(F1,438=5.41;P=.02)、动机更强(F1,272=4.63;P=.03)及筛查到基线改善更小(F1,421=59.32;P<.001)与安慰剂组MCCB更大改善相关。

关键数值与推荐

  • 基线MCCB总分平均低于常模22.8分(约2.28 SD)。
  • 安慰剂相关平均改善小于0.2 SD,提示无天花板效应。

临床怎么用

  • 精神分裂症认知试验中安慰剂组改善微小,不应将练习效应误判为安慰剂效应。
  • 基线抑郁焦虑、动机及筛查到基线变化可影响安慰剂反应,分析时应考虑。

局限性

  • 仅纳入安慰剂组数据,未比较不同药物或试验设计的影响。
  • 研究主要来自门诊患者,结论推广需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients' previous experience with performance-based cognitive tests in clinical trials for cognitive impairment associated with schizophrenia can create practice-related improvements. Placebo-controlled trials for cognitive impairment associated with schizophrenia are at risk for these practice effects, which can be difficult to distinguish from placebo effects. OBJECTIVES: To conduct a systematic evaluation of the magnitude of practice effects on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) in cognitive impairment associated with schizophrenia and to examine which demographic, clinical, and cognitive characteristics were associated with improvement in placebo conditions. DESIGN, SETTING, AND PARTICIPANTS: A blinded review was conducted of data from 813 patients with schizophrenia who were treated with placebo in 12 randomized placebo-controlled clinical trials conducted mostly in outpatient clinics in North America, Europe, Asia, and Latin America from February 22, 2007, to March 1, 2014. A total of 779 patients provided data for the primary outcome measure at baseline and at least 1 follow-up. Seven trials had prebaseline assessments wherein the patients knew that they were not receiving treatment, allowing a comparison of practice and placebo effects in the same patients. INTERVENTIONS: Placebo compared with various experimental drug treatments. MAIN OUTCOMES AND MEASURES: Composite score on the MCCB. RESULTS: Of the 813 patients in the study (260 women and 553 men; mean [SD] age, 41.2 [11.5] years), the mean MCCB composite score at baseline was 22.8 points below the normative mean, and the mean (SEM) total change in the MCCB during receipt of placebo was 1.8 (0.2) T-score points (95% CI, 1.40-2.18), equivalent to a change of 0.18 SD. Practice effects in the 7 studies in which there was a prebaseline assessment were essentially identical to the postbaseline placebo changes. Baseline factors associated with greater improvements in the MCCB during receipt of placebo included more depression/anxiety (F1,438 = 5.41; P = .02), more motivation (F1,272 = 4.63; P = .03), and less improvement from screening to baseline (F1,421 = 59.32; P < .001). CONCLUSIONS AND RELEVANCE: Placebo effects were minimal and associated with the number of postbaseline assessments and several patient characteristics. Given that the patients performed 2.28 SDs below normative standards on average at baseline, a mean placebo-associated improvement of less than 0.2 SD provides evidence that ceiling effects do not occur in these trials. These minimal changes in the MCCB could not be responsible for effective active treatments failing to separate from placebo.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Keefe RSE, Davis VG, Harvey PD, et al. Placebo Response and Practice Effects in Schizophrenia Cognition Trials. JAMA Psychiatry. 2017. PMID: 28636694. doi:10.1001/jamapsychiatry.2017.1574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。